Therapeutic ultrasound for brain disorders


Given the neurosurgical specialty of Professor Carpentier, the SonoProbe was designed for the treatment of brain disorders including brain tumors, epilepsy, metastases, meningiomas, … whose annual incidence in Europe and the USA exceeds 400,000 patients. These are indications that will be developed in future clinical studies.

In addition, the SonoProbe is adaptable for the treatment of diseases in organs such as the lung or in organs located behind bone structures such as the liver.



The primary objective of the SonoCloud® implant is to increase the intracerebral bioavailability of chemotherapy. It is therefore perfectly suited to the treatment of primary brain tumors (gliomas, glioblastomas, astrocytomas, …) as well as secondary brain tumors (metastases) … thus, the annual incidence in Europe and the USA exceeds 250,000 patients. The clinical study currently underway is for patients with glioblastoma.

More generally, the SonoCloud® implant allows for the passage of many substances that are currently not able to enter the brain because of the blood-brain barrier. It can therefore be a potential tool for the treatment of neurodegenerative diseases such as Alzheimer’s Disease.

  • unnamed-2

  • News CarThera

    ASCO 2018: CarThera presents promising preliminary efficacy data for treating recurrent glioblastoma

    Preliminary data from the first clinical trial of the company’s intracranial ultrasound implant, SonoCloud®, show a good safety profile and promising trends in overall survival.

    Dr. Ahmed Idbaih, AP-HP principal investigator of the Phase 1/2a clinical trial (NCT02253212) presented a preliminary analysis of the data from 21 glioblastoma patients who received 65 SonoCloud® treatments. Overall Survival was increased from 8.5 to 12.9 months in patients who had SonoCloud®-induced BBB opening.

    May 2018 – CarThera will participate to BIO 2018 in Boston

    CarThera will participate to the BIO International Convention in Boston on June 4-7 to meet with global biotech and pharma leaders and showcase its SonoCloud device.

    Should you want to meet us at BIO and hear more about SonoCloud – our ultrasound device, aimed at improving treatment efficiency by temporarily opening the Blood Brain Barrier – contact us at and come to Booth 527 at the France Pavilion.

    CarThera presented data from phase 1/2a study at 2017 ASCO annual meeting

    June 2017 – Dr. Ahmed Idbaih, AP-HP principal investigator of the Phase 1/2a clinical trial (NCT02253212) on ultrasound induced Blood-Brain Barrier opening revealed preliminary safety and efficacy data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

    The clinical data from the trial involving 21 patients with recurrent glioblastoma, who have all been treated with SonoCloud® low-intensity pulsed ultrasound in a total of 65 sessions, have been shared with more than 30,000 oncology professionals from around the world.